Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6946 to 6960 of 8213 results

  1. Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]

    In development Reference number: GID-TA11771 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. The Assurance Nasal Alar SpO2 Sensor (discontinued)

    Discontinued Reference number: GID-MT510

    Medical technologies guidance
    Discontinued

  3. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    Discontinued Reference number: GID-TA11476

    Technology appraisal guidance
    Discontinued

  4. Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]

    Discontinued Reference number: GID-TA11009

    Technology appraisal guidance
    Discontinued

  5. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    Discontinued Reference number: GID-TA11318

    Technology appraisal guidance
    Discontinued

  6. Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]

    Discontinued Reference number: GID-TA11007

    Technology appraisal guidance
    Discontinued

  7. Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]

    Discontinued Reference number: GID-TA10937

    Technology appraisal guidance
    Discontinued

  8. Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]

    Discontinued Reference number: GID-TA10917

    Technology appraisal guidance
    Discontinued

  9. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    In development Reference number: GID-TA11265 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]

    In development Reference number: GID-TA11475 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development Reference number: GID-TA11253 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    In development Reference number: GID-TA11001 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    In development Reference number: GID-TA11302 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]

    In development Reference number: GID-TA11366 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]

    In development Reference number: GID-TA11627 Expected publication date: TBC

    Technology appraisal guidance
    In development